DC50292A

Primary objective To evaluate the safety and tolerability of DC50292A tablets in patients with advanced or metastatic solid tumors with MTAP deletion, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended dose (RP2D) for phase II clinical trials. Secondary objective To evaluate the pharmacokinetic (PK) characteristics of DC50292A tablets in patients with advanced or metastatic solid tumors with MTAP deletion; To preliminarily evaluate the anti-tumor efficacy of DC50292A tablets in patients with advanced or metastatic solid tumors with MTAP deletion. Exploratory objective To explore the changes in SDMA levels in serum/tumor tissues from baseline and their correlation with the dose, plasma exposure, and anti-tumor activity of DC50292A tablets by correcting the QTc interval; To explore the changes in ctDNA in plasma from baseline and their correlation with the dose, plasma exposure, and anti-tumor activity of DC50292A tablets. And PK (PK/QTc) to evaluate cardiac safety.